MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.

MLA

Zhang, Hanghang, et al. “MC180295 Is a Highly Potent and Selective CDK9 Inhibitor with Preclinical in Vitro and in Vivo Efficacy in Cancer.” Clinical Epigenetics, vol. 16, no. 1, Jan. 2024, pp. 1–14. EBSCOhost, https://doi.org/10.1186/s13148-023-01617-3.

APA

Zhang, H., Huang, C., Gordon, J., Yu, S., Morton, G., Childers, W., Abou-Gharbia, M., Zhang, Y., Jelinek, J., & Issa, J.-P. J. (2024). MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer. Clinical Epigenetics, 16(1), 1–14. https://doi.org/10.1186/s13148-023-01617-3

Chicago

Zhang, Hanghang, Chen Huang, John Gordon, Sijia Yu, George Morton, Wayne Childers, Magid Abou-Gharbia, Yi Zhang, Jaroslav Jelinek, and Jean-Pierre J. Issa. 2024. “MC180295 Is a Highly Potent and Selective CDK9 Inhibitor with Preclinical in Vitro and in Vivo Efficacy in Cancer.” Clinical Epigenetics 16 (1): 1–14. doi:10.1186/s13148-023-01617-3.